Clovis Oncology Inc CLVS:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 5:55 PM EDT
1.36quote price arrow down-0.01 (-0.73%)
Volume
11,291
Close
1.37quote price arrow down-0.05 (-3.52%)
Volume
1,764,647
52 week range
0.58 - 5.00
Loading...
  • Open1.39
  • Day High1.39
  • Day Low1.31
  • Prev Close1.42
  • 52 Week High5.00
  • 52 Week High Date08/30/21
  • 52 Week Low0.58
  • 52 Week Low Date06/13/22

Key Stats

  • Market Cap197.94M
  • Shares Out144.48M
  • 10 Day Average Volume4.69M
  • Dividend-
  • Dividend Yield-
  • Beta0.39
  • YTD % Change-49.45

KEY STATS

  • Open1.39
  • Day High1.39
  • Day Low1.31
  • Prev Close1.42
  • 52 Week High5.00
  • 52 Week High Date08/30/21
  • 52 Week Low0.58
  • 52 Week Low Date06/13/22
  • Market Cap197.94M
  • Shares Out144.48M
  • 10 Day Average Volume4.69M
  • Dividend-
  • Dividend Yield-
  • Beta0.39
  • YTD % Change-49.45

RATIOS/PROFITABILITY

  • EPS (TTM)-1.99
  • P/E (TTM)-0.69
  • Fwd P/E (NTM)-1.12
  • EBITDA (TTM)-208.80M
  • ROE (TTM)-547.55%
  • Revenue (TTM)140.27M
  • Gross Margin (TTM)72.76%
  • Net Margin (TTM)-187.71%
  • Debt To Equity (MRQ)-175.93%

EVENTS

  • Earnings Date11/01/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Clovis Oncology Inc

Profile

MORE
Clovis Oncology, Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer...
Ginger Graham
Independent Chairman of the Board
Patrick Mahaffy
President, Chief Executive Officer, Co-Founder, Director
Daniel Muehl CPA
Chief Financial Officer, Executive Vice President
Ann Bozeman
Executive Vice President of Human Resources
Paul Gross J.D.
Executive Vice President, General Counsel
Address
Suite 100, 2525 28Th Street
Boulder, CO
80301
United States

Top Peers

SYMBOLLASTCHG%CHG
HBIO
Harvard Bioscience Inc
3.18-0.01-0.31%
SELB
Selecta Biosciences Inc
2.18-0.21-8.79%
RIGL
Rigel Pharmaceuticals Inc
1.62+0.03+1.89%
ATNX
Athenex Inc
0.4924-0.0076-1.52%
XERS
Xeris Biopharma Holdings Inc
1.86+0.01+0.54%